Cyclin D1 proto-oncogene is a key regulator of the mammalian cell-cycle acting at the restriction point in late G1. Ampli®cation of the cyclin D1 locus, located on chromosome 11q13, as well as cyclin D1 protein overexpression have been reported in several human malignancies. The purpose of this study was to evaluate cyclin D1 gene copy status and protein expression during the multistep process of head and neck tumorigenesis, using a combination of¯uorescence in situ hybridization and immunohistochemistry techniques. From 29 selected patients presenting with head and neck squamous carcinoma and whose tumor cytospins had been previously screened for presence (16 cases) or absence (13 cases) of ampli®cation at the 11q13 band, we analysed 46 paran-embedded tissue specimens that demonstrated, besides the primary tumor, the presence of contiguous adjacent normal tissue and/or premalignant lesions. Of the 16 ampli®ed cases, nine demonstrated a continuous progression from premalignant to invasive carcinoma and seven (77.7%) of these cases showed cyclin D1 gene ampli®cation in premalignant lesions prior to development of invasive carcinoma. Increased cyclin D1 protein expression was observed in all 16 ampli®ed tumors and ®ve of the 13 (38.4%) nonampli®ed tumors. Interestingly, dysregulated cyclin D1 expression was also found in the premalignant lesions adjacent to all 16 ampli®ed tumors, and it appeared to precede cyclin D1 gene ampli®cation. In contrast no dysregulated expression was detected in the premalignant lesions of the non-ampli®ed tumors. In conclusion, these ®ndings provide strong evidence for early dysregulation of cyclin D1 expression during the tumorigenesis process and suggest that dysregulated increased expression precedes and possibly enables gene ampli®cation.
Introduction
There is now extensive evidence that, like other epithelial cancers, head and neck squamous cell carcinoma (HNSCC) tumorigenesis evolves over several years and proceeds as a multistep process involving the emergence of genetically altered cell populations in the carcinogen exposed ®eld (Cowan et al., 1992; Califano et al., 1996) .
Cytogenetic and molecular analysis of advanced primary HNSCC and more recently of associated premalignant lesions have identi®ed a variety of common genetic abnormalities. While high frequencies of allelic losses on chromosomal loci harboring putative tumor suppressor genes (e.g. 9p, 3p, 17p, 13q, 18q and 8q) (Nawroz et al., 1994; El-Naggar et al., 1995; Mao et al., 1996) have been described, only a few abnormalities involving candidate proto-oncogenes have been identi®ed in head and neck tumors. Of these, the ampli®cation of a region on chromosome 11q13 is the most frequently reported alteration and occurs in 30 ± 50% of HNSCC (Berenson et al., 1989; Somers et al., 1990; Lammie et al., 1991; Schuuring et al., 1992) .
The 11q13 amplicon is unusually large (spanning 2 ± 5 megabases) and has been shown to encompass several putative oncogenes including protein phosphatase 1a, cyclin D1 (PRAD1/CCND1), FGF4 and FGF3 (formerly known as HST-1 and INT-2), EMS1 and SEA gene (reviewed in Schuuring, 1995) . The driving force leading to ampli®cation and the principal molecular target of the ampli®cation at the 11q13 region remain to be identi®ed. One tauted target candidate is cyclin D1 since it ful®lls several expected characteristics including: location on the amplicon, involvement in all cases of ampli®cation, correlation of level of expression with ampli®cation and selective growth advantage properties (Gaudray et al., 1992; Schuuring, 1995) . Moreover, cyclin D1 rearrangements, ampli®cation and overexpression have been observed in a wide range of human tumors (Motokura et al., 1993a) . Several recent studies conducted in tumor specimens of head and neck cancer patients have suggested that cyclin D1 ampli®cation and/or overexpression may be associated with a poor prognosis (Jares et al., 1994; El-Naggar et al., 1995a; Michalides et al., 1995) .
Cyclin D1 is strongly implicated in cell cycle control and oncogenesis. It participates in the regulation of the phosphorylation status of the retinoblastoma protein (pRb) (Scherr, 1994) and is thought to play a role in driving cells through the restriction point in late G1. Substantial evidence exists to suggest that the level of cyclin D1 protein is critical to proper cell cycle progression and that deregulated expression of cyclin D1 may disrupt cell cycle control and contribute to cellular genomic instability (Almasan et al., 1995) . Indeed, cells overexpressing cyclin D1 have a shortened G1 phase, reduced dependency on exogenous mitogens, abnormal proliferative characteristics (Quelle et al., 1993; Jian et al., 1993) , and demonstrate a higher frequency of gene ampli®cation, especially under genotoxic stress conditions (Zhou et al., 1996) . Moreover, overexpression of cyclin D1 has also been shown to be associated with tumor transformation by in vitro studies in normal ®broblasts and primary embryo cells (Jian et al., 1993; Hinds et al., 1994; Uchimaru et al., 1996) as well as by in vivo studies in transgenic mice (Wang et al., 1994) .
While cyclin D1 abnormalities can be observed in primary HNSCC tumors as well as in HNSCC cell lines, little is known about the role of this protooncogene in the early stages of tumorigenesis. An early report from Bartkova et al. (1995) noted cyclin D1 overexpression in non-involved mucosa near head and neck tumors. However, to our knowledge no study to date has systematically investigated cyclin D1 abnormalities during the multistep process of tumorigenesis. In recent years, in an attempt to identify biological markers that might recognize tissues at risk for cancer, our group has focused on the characterization of cellular genotypic and phenotypic determinants of head and neck tumorigenesis using, as a model system, sections of HNSCC tumors that contain their adjacent premalignant lesions. The rationale behind the use of these tumor sections and their adjacent premalignant lesions is that these would theoretically represent tissue at 100% risk of tumor development. Along with the latter assumption, there is the presumption that an apparent continuous histologic progression, from normal epithelium through hyperplasia and dysplasia to invasive carcinoma, may represent the evolutionary history of the particular tumor. Using this approach we previously demonstrated alterations in the expression of growth regulatory (i.e. epidermal growth factor receptor, p53) and proliferative markers (i.e. proliferating cell nuclear antigen) as well as a generalized genetic instability process (i.e. chromosome polysomy) in the epithelial ®eld of the head and neck tumors and we also showed that these dysregulated processes appear to increase with the transition from normal adjacent epithelium to tumor (Shin et al., , 1994a Voravud et al., 1993) .
In a preliminary study using this model system, we found that gene ampli®cation of FGF3/INT2 could be detected by in situ hybridization in premalignant lesions contiguous to HNSCC tumors (Roh et al., 1994) . Since FGF3/INT2 proto-oncogene is part of the same amplicon as cyclin D1 and since it is not found to be overexpressed in tumors (Gaudray et al., 1992; Brookes et al., 1993) , we were interested in exploring the role of cyclin D1 in this setting. We therefore identi®ed HNSCC cases, undergoing surgical resection, that did or did not exhibit 11q13 ampli®cation in their tumor cells and then examined paran blocks of the resected tumors for the occurrence of the ampli®cation event in adjacent premalignant regions using fluorescence in situ hybridization (FISH). In addition, on adjacent tissue sections, we immunochemically determined the presence and level of cyclin D1 protein expression and evaluated the relationship between cyclin D1 gene ampli®cation and protein expression by further combining FISH and immunohistochemistry (IHC). The results reported here suggest that dysregulated cyclin D1 expression is an early event during head and neck tumorigenesis and that it precedes and may enhance the occurrence of gene ampli®cation in vivo.
Results

Patient and tissue selection and characteristics
The cases analysed in the present study were chosen from 96 HNSCC patients undergoing surgical resection at our Institution, whose resected tumor specimens were large enough to allow the procurement of sucient material for tumor tissue dissociation as well as for adjacent normal and premalignant tissue analyses. Cytospin preparations from 96 fresh tumor specimens were ®rst screened and assessed for ampli®cation of the FGF3/INT2 gene by FISH. Of these, 35 cases showed ampli®cation and 61 showed single copy levels. Since co-ampli®cation at FGF3/INT2 and cyclin D1 loci occurs frequently (Lammie et al., 1991; Tanigami et al., 1992; Junien et al., 1992; Brookes et al., 1993) , we expected that samples harboring FGF3/INT2 gene ampli®cation might also exhibit cyclin D1 ampli®cation. Thereafter, archival pathological paran-embedded resection materials were examined to identify cases where the tissue block specimens contained, besides the tumor, adjacent normal tissue and/or premalignant lesions (i.e. hyperplasia, dysplasia). At last, 29 cases (46 formalin®xed, paran-embedded specimens) met the selection criteria, and of these, 16 cases showed evidence of FGF3/INT2 gene ampli®cation and 13 were single copy. Twenty-six of the 29 cases showed adjacent normal epithelium (26 sites), 29 cases contained hyperplasia (34 sites) and dysplasia (31 sites) and eight cases demonstrated carcinoma in situ (CIS). Twelve of these cases demonstrated evident continuous histologic progression from adjacent normal epithelium through hyperplasia, dysplasia and CIS into invasive carcinoma. All tumors were epidermoid SCC and they were graded as: well dierentiated (three cases), moderately dierentiated (15 cases) and poorly dierentiated (11 cases).
The examined cases presented with the typical clinical characteristics of the HNSCC population. There was an overrepresentation of clinical stages III and IV, and this likely re¯ects our specimen selection criteria requiring large tumors. All but two of the patients had a documented history of heavy smoking and 23 of 29 were current smokers. Most patients (21 of 29) were also current drinkers. Four of 29 (14%) presented with previously treated HNSCC (two local lesions appearing after two years and two second primaries).
Cyclin D1 gene ampli®cation during HNSCC multistep tumorigenesis
To determine the cyclin D1 gene copy status we hybridized patient tissue sections with a cyclin D1 plasmid probe combined with an a-satellite probe speci®c for chromosome 11 using dual-colour FISH. The use of the chromosome 11 centromeric probe was intended to distinguish an increased copy number due to gene ampli®cation from chromosome 11 polysomy (Kallioniemi et al., 1992; Sauter et al., 1995) . A site was de®ned as having cyclin D1 gene ampli®cation when the average cyclin D1 copy number per centromere 11 per tumor was greater than two.
Of the 29 tumors analysed, the 13 selected because they appeared to have no FGF3/INT2 ampli®cation harbored cyclin D1 single copy gene status. Interestingly, 4 of these 13 tumors demonstrated chromosome 11 polysomy (i.e. more than two centromeric signals per cell). In these cases single copy cyclin D1 signals appeared to co-localize with each of the centromeric chromosome 11 signals ( Figure 1a ). As predicted, all 16 tumors previously identi®ed as ampli®ed at the FGF3/ INT2 locus also harbored cyclin D1 gene ampli®cation ( Figure 1b) . Although some intratumoral, randomly distributed, heterogeneity in copy number per cell was observed (most likely re¯ecting nuclear truncation due to tissue sectioning), all ampli®ed tumor cases showed cells with high levels of cyclin D1 gene copy number, usually more than 10 copies per tumor cell. Stromal cells and in®ltrating lymphocytes were negative for gene ampli®cation and served as an internal control.
Nine of the 16 ampli®ed tumor cases demonstrated evidence of a continuous histologic progression from premalignant lesions to invasive cancer. In seven of these nine cases (77.7%), cyclin D1 gene ampli®cation was visualized in premalignant lesions adjacent to invasive tumor ( Figure 1c ). Four cases showed ampli®ed cells expanding in mildly dysplastic lesions, which carried through to invasive tumor and three cases exhibited cyclin D1 ampli®cation at the severe dysplasia-CIS transition. Of interest, the appearance of the ampli®ed signals was similar in the premalignant lesions and in the tumors with respect to pattern of the signal and the copy number, suggesting that the ampli®cation event occurred at one point during tumor development rather than gradually. In none of these cases did the appearance of ampli®cation seem to be related to tumor cell in®ltration into premalignant lesions. To con®rm this observation, the sections adjacent to the hybridized slides were stained with hematoxylin-eosin and were subjected to histologic evaluation. In all cases histologic analysis showed: (a) the presence of an intact basement membrane con®ning the ampli®ed cells and (b) the morphologic characteristics of dysplasia of the ampli®ed cells.
To further determine whether ampli®cation of FGF3/INT2 and cyclin D1 occurred together or as separate events, dual-color FISH analysis was carried out using cyclin D1 and FGF3/INT2 genomic probes. We found that these two genes were always coampli®ed not only in the tumors ( Figure 1d ) but also in the premalignant lesions that harbored early gene Note the co-localization of the ampli®ed signals resulting in a yellow signal and the presence of in®ltrating lymphocytes harboring the two co-localized distinctly single copy signals ampli®cation. Moreover, when present as single copy, the two genes always appeared as co-localized single dots.
Increased expression of cyclin D1 in HNSCC tumors
To examine the relationship between cyclin D1 ampli®cation and cyclin D1 protein expression in the HNSCC tumors, adjacent tissue sections were immunohistochemically characterized with a polyclonal antibody to cyclin D1. It should be noted that the polyclonal antibody used in this study recognizes both cyclin D1 and D2 proteins. However, several studies have shown that epithelial cells and HNSCC tumors preferentially express cyclin D1 (Tam et al., 1994; Lukas et al., 1995; Bartkova et al., 1995) . In addition, the staining was con®rmed with the monoclonal anticyclin D1 antibody DCS-6 (Neo-Markers, Fremont, California), known to recognize only cyclin D1 .
All 16 tumor specimens harboring cyclin D1 gene ampli®cation were positive for cyclin D1 expression (i.e. labeling indices 410%) (Figure 2a ). Of these, 14 (87.5%) cases expressed high cyclin D1 levels, while two (12.5%) cases expressed moderate levels in the tumor regions (Table 1) . Increased cyclin D1 expression was also seen in ®ve (38.5%) of the 13 nonampli®ed tumor cases (one strong and four moderate Figure 2 Immunohistochemical demonstration of cyclin D1 dysregulated expression in head and neck tumorigenesis. Strong positive staining of (a) tumor harboring cyclin D1 gene ampli®cation, note the downregulation of cyclin D1 overexpression in the keratins pearls; (b) dysplastic and (c) hyperplastic epithelium adjacent to the tumor. Weak/negative staining of (d) tumor with no detectable cyclin D1 gene ampli®cation; (e) dysplastic and (f) hyperplastic epithelium adjacent to the tumor. Note that in all cases stromal cells and lymphocytes were negative staining). Interestingly, four of these ®ve cases had showed multiple single copies of the cyclin D1 gene associated with chromosome 11 polysomy. The remaining eight single copy tumors showed either weak staining (six cases) or were completely negative (two cases) (Figure 2d ).
The cyclin D1 protein signal was distinctly nuclear in all cases, however there was a heterogeneous pattern of staining intensity within the tumors. The strongly stained cells were predominantly observed in the undierentiated and/or proliferative zones of the tumors, whereas the majority of the cells were weakly positive or negative in more dierentiated tumor regions (such as the keratin pearls), even when harboring cyclin D1 gene ampli®cation (Figure 2a) . Moreover, particularly in the non-ampli®ed overexpressing tumors, the nuclear staining intensity varied from cell-to-cell within same positive region, perhaps re¯ecting the cell cycle-related oscillations of cyclin D1 protein level. In®ltrating lymphocytes do not express cyclin D1 (Ajchenbaum et al., 1993) and therefore served as negative internal controls for each section.
Evidence for early dysregulation of cyclin D1 expression in premalignant lesions
Since, in some cases, cyclin D1 ampli®cation was observed in adjacent premalignant lesions, it was of interest to examine the temporal and spatial relationship between cyclin D1 gene ampli®cation and increased protein expression during multistep tumorigenesis. Immunohistochemical examination of cyclin D1 expression was carried out in tissue sections of all 29 cases and demonstrated a striking dierence between cyclin D1 ampli®ed and non-ampli®ed cases. All 16 ampli®ed cases demonstrated dysregulated cyclin D1 protein expression in their adjacent premalignant lesions (Figure 2b and c) . In contrast none of the 13 non-ampli®ed cases showed increased expression in the adjacent premalignant tissues (Table 1) (Figure 2e and f). Rather, a small fraction (less than 3%) of weakly to moderately stained cells was observed, usually con®ned to the basal layer.
In the 16 cases with cyclin D1 ampli®cation, increased cyclin D1 expression was observed in 18 of 20 (90%) adjacent hyperplastic lesions and 16 of 18 (88%) adjacent dysplastic lesions. Cyclin D1 increased expression ®rst appeared as distinct foci of nuclear staining involving predominantly basal and parabasal cells, whereas the majority of the cells in the super®cial layers were negative (see Figure 2b and c) (see Table 2 ). This might suggest a downregulation of cyclin D1 protein expression upon dierentiation, even in the dysregulated setting. Moreover, as tissues histologically progressed toward tumor, the frequency of cyclin D1-positive cells increased continuously. As shown in Table 3 , no positive cells were found in normal tissue, 35.6% positive cells were observed in hyperplasia, 55.2% in dysplasia and 80.8% in CIS. These results suggest that dysregulated cyclin D1 protein expression might precede cyclin D1 gene ampli®cation.
To better examine the potential relationship between the levels of cyclin D1 protein expression and cyclin D1 gene ampli®cation, we spatially recorded the location of these events on tissue sections using an image analysis system and then presented the results as twodimensional digitized map of cyclin D1 protein expression and gene ampli®cation in a premalignant epithelial ®eld progressing toward invasive cancer (Figure 3) . Interestingly, in the nine cases exhibiting gene ampli®cation in premalignant lesions, the cellular accumulation of cyclin D1 clearly spatially preceded the occurrence of the ampli®cation event.
Discussion
The study described here, combining FISH and IHC techniques, provides novel evidence that: (a) cyclin D1 gene ampli®cation can occur in histologically con®rmed premalignant lesions adjacent to invasive carcinoma; and (b) dysregulated expression of cyclin D1 protein is an early event during head and neck tumorigenesis, perhaps preceding the occurrence of gene ampli®cation.
Tumorigenesis is postulated to be an accumulation of genetic alterations, in some cases driven by continued carcinogenic exposure, resulting in phenotypic changes that aect cell growth, dierentiation, cell loss and function and may culminate in the acquisition of a fully transformed tumor phenotype (Farber, 1996) . In head and neck cancer, several recent studies have focused on the characterization of generalized genomic instability and the acquisition of the speci®c genetic and phenotypic changes accompanying tumor development in an attempt to de®ne a 
2 4 (4) 7 (8) 7 (7) 6 6 (9) 6 (6) 2 (2) 4 0 0 0 1 0 0 0 *In these cases the section contained dierent areas of hyperplastic/dysplatic lesions demonstrating negative or weak staining when spatially distant from the tumor and positive staining when immediately adjacent to the tumor tumor progression model (Cowan et al., 1992; Boyle et al., 1994; Shin et al., 1994a,b; Soder et al., 1995; Califano et al., 1996) . Most of the early speci®c genetic changes previously described involve mutations, deletions, loss of heterozygosity and chromosomal rearrangements. In contrast, the timing of gene ampli®cation is less well understood and several studies have suggested that proto-oncogene amplification is observed late in the progression of many tumors (reviewed in Brison, 1993; Lese et al., 1995) . This has been supported, in the past, by the in vitro-derived notion that permissiveness for ampli®cation requires the disruption of several checkpoint mechanisms, often a hallmark of transformed cells. However, recent studies suggest that disruption of speci®c genes in untransformed cells can make cell permissive for gene ampli®cation and that this can occur prior to immortalization (Tlsty et al., 1993; Tainsky et al., 1995) . It is therefore possible that cells exposed to continued carcinogen insult might be more susceptible to the accumulation of genetic damage and therefore may acquire the competence for gene ampli®cation prior to developing a full tumorigenic phenotype. This hypothesis is supported by our present observation of cyclin D1 gene ampli®cation in premalignant lesions adjacent to head and neck tumors. It should be emphasized that an important aspect of this study has been the careful choice of specimens exhibiting apparent continuous progression, from adjacent normal epithelium through hyperplasia to dysplasia to tumor. This has provided us with the ability to visualize the history of the multistep tumorigenesis process on a case-by-case basis and to directly explore the relationship between speci®c genetic changes, clonal evolution of the genetically altered cells, and histopathological progression toward tumor. The ®nding that cyclin D1 gene ampli®cation can be detected in premalignant lesions and that the ampli®ed signals (in terms of pattern and level of copy number as well as the coincident co-ampli®cation of (17) HYP (20) DYS (18) SCC (16) b ANL: normal epithelium adjacent to tumor; HYP: hyperplasia; DYS: dysplasia; SCC: squamous cell carcinoma FGF3/INT2) are similar between the adjacent premalignant lesions and the tumors suggest the possibility that an ampli®ed clone emerged in premalignant lesions and remained during the subsequent clonal evolution to invasive cancer. This possibility is consistent with the detection of allelic imbalances at the 11q13 locus in premalignant lesions (up to 6% in hyperplasia, 29% in dysplasia and 40% in CIS) adjacent to HNSCC tumors, likely re¯ecting an ampli®cation event (Califano et al., 1996) . The use of dual-color FISH with probes for the centromeric region of chromosome 11, cyclin D1 and FGF3/INT2 genes, has allowed new insight into the in vivo mechanisms of gene ampli®cation (i.e. double minute versus intrachromosomal ampli®cation, expression of fragile sites) that are being currently analysed.
The study reported here indicates that in HNSCC tumors, cyclin D1 ampli®cation was highly correlated with increased cyclin D1 expression. Indeed all 16 ampli®ed tumor cases showed high expression of cyclin D1. On the other hand, not all ampli®cation events are associated with increased gene product expression (e.g. FGF3/INT2), thus suggesting that some regulatory control of expression must still be present in the ampli®ed regions. This notion is further supported by the observation, reported here as well as by other investigators (Bartkova et al., 1994 , of the heterogeneous staining pattern within tumors and the downregulation of cyclin D1 protein levels in association with dierentiation, even in tumors harboring cyclin D1 ampli®cation. Interestingly, four of the ®ve non-ampli®ed tumors that demonstrated increased expression also exhibited multiple single copies of the cyclin D1 gene associated with chromosome 11 polysomy. This suggests that dysregulation of cyclin D1 expression can occur through several mechanisms including chromosome 11 polysomy, DNA amplification and protein post-translational regulation, as previously suggested by .
Interestingly dysregulated cyclin D1 expression in premalignant lesions was preferentially observed in those cases that ultimately exhibited cyclin D1 gene ampli®cation in the tumors. This observation raises three points of interest. First, dysregulation of cyclin D1 levels may enhance permissiveness for gene amplification in general. For example, Zhou et al. (1996) showed that stable overexpression of cyclin D1 was associated with increased rates of CAD gene ampli®cation. In this case, the experiment was performed to speci®cally select CAD ampli®ed cells under PALA pressure. The mechanism underlying the association between overexpression of cyclin D1 and gene ampli®cation is not well understood. However, several in vitro studies have demonstrated that premature expression (or stable overexpression) of cyclin D1 in early G1 may lead, through immediate pRb hyperphosphorylation, to a premature release from the G1 phase and a consequent inappropriate entry in S-phase (Almasan et al., 1995) . Even in the setting of genotoxic insult, cyclin D1 overexpression induces a premature release from the G1 phase despite a p53-mediated induction of the cyclindependent-kinase inhibitor p21 WAF1 protein (Zhou et al., 1996) . Therefore one would predict that cells exhibiting dysregulated and/or premature expression of cyclin D1 might have lost the ability to inhibit the cell cycle in G1 and S phases in the face of DNA damage. Proliferation under these conditions may result in genomic instability, as measured by the ability of these cells to undergo gene ampli®cation (Zhou et al., 1996) . This process might be important in the setting of head and neck tumorigenesis where chronic tobacco and alcohol exposure provide continuous genotoxic insult, and cyclin D1 overexpression may serve to accentuate genetic instability. Indeed, preliminary studies, conducted in the same HNSCC tissues described here, suggest the concurrence of increased genomic instability in regions of cyclin D1 overexpression (Izzo et al., 1997) .
A second point of interest is that since in our study cyclin D1 dysregulation led to the generation of cyclin D1 ampli®ed cells, it might suggest that dysregulated increased expression of cyclin D1 allows selective outgrowth in the in vivo setting and therefore play an important role in tumorigenesis. Interestingly, previous studies conducted in premalignant lesions of several tumor types, including colorectal cancer (Arber et al., 1996a) , esophageal adenocarcinoma (Arber et al., 1996b) and laryngeal cancer (Uhlman et al., 1996) have reported increased cyclin D1 expression in a fraction of premalignant tissues and have also suggested that increased expression of cyclin D1 may be an early event predisposing for transformation.
A third point of interest is the observation that dysregulated cyclin D1 expression preceded amplification at the cyclin D1 locus and was not found in the premalignant lesions of non-ampli®ed tumors. This might suggest that cyclin D1 overexpression targets itself for genetic instability, perhaps along with other early replicating genes (possibly more transcriptionally active). Whether this targeted instability is due to upregulation of fragile sites in the chromosome regions (Kuo et al., 1994; Coquelle et al., 1997) or is due to the increased accessibility of transcriptionally active regions to carcinogen attack (Bohr, 1988) remains to be determined.
In conclusion, the present study demonstrates in an in vivo model of multistep head and neck tumorigenesis that dysregulated cyclin D1 expression occurs early in the tumorigenesis process and possibly contributes to cellular malignant transformation by dysregulating cell proliferation and enabling gene ampli®cation. Additionally, we also have demonstrated that gene ampli®cation may occur early in premalignant lesions and therefore may cooperate with other genetic alterations in the acquisition of the cellular tumorigenic properties. Since the majority of the cases reported in this study were advanced clinical stages and histological poorly differentiated tumors, it is not known whether these conclusions will apply to less advanced stage or more dierentiated lesions. Further studies of the mechanisms underlying this process as well as its association with other genomic instability processes, such as chromosome aneuploidy, are currently in progress.
Materials and methods
Tumor specimens
Hematoxylin-eosin stained slides from archival tumor specimens were reviewed by a pathologist from the Department of Pathology at The University of Texas, MD Anderson Cancer Center (JYR). Representative blocks that contained carcinoma as well as adjacent normal and premalignant lesions were selected. The criteria used to de®ne premalignant lesions, including hyperplasia and dysplasia, were as previously described (Cotran et al., 1992) . Four-mm sections from the blocks were mounted on aminoalkylsilane-coated slides (Histology Control System, Glen Head, NY) and stored at room temperature. Serially cut sections were used for FISH and IHC to allow matched spatial comparisons. Cell pellets were generated from a head and neck carcinoma cell line (MDA 886) carrying cyclin D1 gene ampli®cation and protein overexpression. These cell pellets were ®xed in formalin, embedded in paran, and four-mm sections from this paran block were used as positive controls for in situ hybridization and IHC.
DNA probes and in situ hybridization
A plasmid probe spanning 16 kb of the cyclin D1 gene (Motokura et al., 1993b) was kindly provided by Dr A Arnold (Massachusetts General Hospital, Boston); the 40 kb cosmid probe speci®c for FGF3/INT2 was kindly provided by Dr M Tainsky (UT MD Anderson, Houston). A digoxigenin-labeled or biotin-labeled peri-centromeric asatellite probe speci®c to chromosome 11 (D11Z1) was obtained from Oncor (Gaithersburg Inc.). Both plasmid and cosmid probes were labeled with digoxigenin-11dUTP or biotin-16dUTP (Boehringer, Mannheim) by nick translation, using optimized conditions to generate a probe size of 300 ± 600 bp.
Dual-color FISH technique was carried out as previously described (Lutz et al., 1992) with modi®cations. Brie¯y, after deparanation with xylene, the tissue sections were rehydrated through a graded ethanol series down to 30%, re®xed in 4% paraformaldehyde, washed with PBS (phosphate-buered saline), and incubated in 26SCC (30 mM sodium chloride, 3 mM sodium citrate) at 378C for 30 min. Subsequently, the tissue sections were digested with proteinase K (Boehringer, Mannheim; 20 mg/ml at 558C for 20 min) followed, after washing in distilled water, by pepsin (Sigma Chemical Co., St Louis, MO; 4 mg/ml in 0.9% NaCl) for 15 min at 378C; then the slides were rinsed with distilled water, dehydrated with ethanol and air-dried. The specimens were denatured at 758C for 5 min in denaturation solution (70% formamide, 26SCC) and then dehydrated in an ice-cold graded ethanol series. Two hundred and ®fty ng of cosmid DNA was coprecipitated with 8 mg of Cot-1 DNA (Boehringer, Mannheim), dissolved in 15 ml of hybridization mixture (Hybrisol VIII, Oncor, Gaithersburg), denatured at 758C for 5 min and preannealed at 378C for 30 min. Fifteen ng of centromeric probe was prepared as described above but without Cot-1 DNA addition and preannealing. The plasmid DNA and centromeric probes were applied onto denatured slides and the hybridization was carried out in a moist chamber at 378C for 48 h. Posthybridization washes were performed in 50% Formamide ± 26SCC, pH 7 at 438C for 10 min (three times), 0.16SCC at 438C for 8 min twice and 26SCC for 5 min at room temperature followed by preblocking with 3% bovine serum albumin/46SCC for 15 min at 378C. The biotin-labeled probes were detected by FITC-avidin (15 mg/ml, Vector Laboratories, Burlingame, CA), biotin-conjugated antiavidin (5 mg/ml, Vector Laboratories), and a second layer of FITC-avidin for 30 min each. Digoxigenin-labeled probes were detected by Rhodamine-conjugated sheep antidigoxigenin antibody (Oncor, Gaithersburg), rabbit anti-sheep antibody followed by anti-rabbit Rhodamine-conjugated antibody for 30 min each. DNA was counterstained with 0.1 mM DAPI (4,5-diamino-2-phenylindole) in an antifade solution (Oncor, Gaithersburg).
Fluorescence microscopy and scoring criteria
The¯uorescent signals on slides were examined with a Nikon OPTIPHOT epi¯uorescence microscope equipped with 40 and 1006 oil-immersion objective and triple bandpass ®lter for DAPI/FITC/Texas Red. Two observers (JI, XQL) performed independent evaluation of the FISH slides in a blinded manner. FISH was considered evaluable if the following criteria were met: (1) preservation of nuclei with intact morphology on the basis of DNA staining; (2) uniform hybridization throughout the section; and (3) single copy status could be positively identi®ed. Partially or completely overlapping nuclei were ignored and`split' centromere signals were counted as one. A minimum of 250 nuclei were analysed per section and per histological area if possible (depending on cell yield). A tumor was considered ampli®ed if the average cyclin D1 copy number per centromere 11 signal per scored cell exceeded two. This cuto was established based on previous studies that demonstrated reliable equivalence between ampli®cation analysis by FISH and slot blot analysis (Kallioniemi et al., 1992) . In®ltrating tumoral lymphocytes served as internal controls for hybridization eciency and sectioning artefacts.
Immunohistochemistry and staining assessment
Anti-Cyclin D1 rabbit polyclonal antibody (generated against the C-terminal moiety corresponding to amino acids 285 ± 295) was obtained from UBI (Upstate Biotechnology, Lake Placid, NY). Brie¯y, deparanized and rehydrated sections were blocked for endogenous peroxidase activity by 3% H 2 O 2 in methanol. The sections were then placed in 10 mM citrate buer (pH 6.0) and microwaved at 630 W for 16 min (in 4 min intervals). After treatment with goat blocking serum, the slides were incubated with a 1 : 200 dilution (10 mg/ml) of primary antibody at 48C overnight. Subsequently the slides were washed and incubated with 1 : 250 dilution of biotinylated anti-rabbit secondary antibody for 1.5 h at 378C and then with 1 : 1000 dilution of biotin-avidin-peroxidase conjugate (Vector Laboratories, Burlingame, CA) for 30 min at room temperature. After washing, the slides were incubated for antigen visualization with 3-3'-diaminobenzidine tetrachloride (Sigma Chemical Co. St Louis, MO; 1 mg/ml in 16PBS) and H 2 O 2 (30 ng/ml) substrate, and then counterstained with Mayer's hematoxylin or Methyl-green and mounted in Eukitt. Intratumoral lymphocytes served as negative internal controls for cyclin D1 expression in each slide and positive controls included tissue sections of MDA 886 cell pellets placed on the same slide. A semiquantitative scoring procedure was carried out on the basis of the intensity of nuclear staining using a 4 point scale where a score of 0 represents no staining, a score 1±weak staining, score 2±moderate and score 3±strong staining. Cases showing moderate or greater staining in 10% or more of the cells were regarded as positive for the purpose of the analysis. Labeling indices were determined in tumor, adjacent normal and premalignant lesions by counting at least 200 cells in each of three dierent areas. For premalignant lesions and adjacent normal epithelia, the three layers (i.e. basal, parabasal and super®cial) were identi®ed, counted and assessed separately. The labeling index of cyclin D1 was calculated as the total number of positively stained cells (score52) divided by the total number of cells counted.
Topographical maps of cyclin D1 ampli®cation and expression
To create a spatial visualization of the distribution of cyclin D1 expression patterns, we analysed the slides using the Magiscan Image Analysis System (Joyce-Loebl, Ltd., Dukesway, England) attached to a Nikon light microscope with a controller-driven stage. Using a light pen, each scored cell was at ®rst recorded for positive or negative staining and its relative spatial coordinates in the epithelial layers of the tumor. Subsequently, using software previously developed in our laboratory, a topological map of cyclin D1 expression was constructed displaying the results as a two-dimensional color map where the degree of expression was represented by dierent colors. The coordinates relative to the FISH signals were ®rst collected by using a microslide ®eld ®nder displaying an imprinted grid of 1 mm squares subdivided into 0.1 mm intervals. Subsequently a combined map was constructed by integrating FISH and IHC coordinate data.
